Chemistry:5-IAI
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral, Insufflated, Rectal |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C9H10IN |
| Molar mass | 259.090 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
5-Iodo-2-aminoindane (5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine.[1] It was developed in the 1990s by a team led by David E. Nichols at Purdue University.[2] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans.[2] Unlike related aminoindane derivatives like MDAI and MMAI, 5-IAI causes some serotonergic neurotoxicity in rats, but is substantially less toxic than its corresponding amphetamine homologue pIA, with the damage observed barely reaching statistical significance.[1]
Legal status
Sweden's public health agency suggested classifying 5-IAI as a hazardous substance, on September 25, 2019.[3]
References
- ↑ 1.0 1.1 "[3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues". European Journal of Pharmacology 200 (1): 9–16. July 1991. doi:10.1016/0014-2999(91)90659-E. PMID 1685125.
- ↑ 2.0 2.1 "5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine". Pharmacology Biochemistry and Behavior 38 (1): 135–9. January 1991. doi:10.1016/0091-3057(91)90601-W. PMID 1826785.
- ↑ "Tretton ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in sv). Folkhälsomyndigheten. 25 September 2019. https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2019/september/tretton-amnen-foreslas-klassas-som-narkotika-eller-halsofarlig-vara/.
 |  |
